Artiva surges on US FDA's 'fast track' tag for rheumatoid arthritis therapy

Artiva Biotherapeutics

17/10/2025 15:40

Updates

** Shares of drug developer Artiva ARTV.O surge 92% to $5.32, its highest daily percentage gain in seven months

** Co on Thursday said U.S. FDA granted fast track designation to its cell therapy AlloNK for treating refractory rheumatoid arthritis

** "Fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** Refractory rheumatoid arthritis is a chronic joint disease

** Over 20 patients tested with AlloNK plus antibody therapy across autoimmune trials, including RA and lupus - ARTV

** Lupus is a chronic autoimmune disease where the body's immune system mistakenly attacks its own tissues and organs

** Including session's move, stock down ~47% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.pandey@thomsonreuters.com))